Modulation of bile acid signaling via bile acid receptor agonists inhibits bile acid biosynthesis [117], alleviates metabolic syndromes [100], ameliorates dysbiosis [47], and improves the histology of NAFLD [99]. The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatotic liver disease.